AVITA Medical Updates Expected First Quarter 2024 Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
BTIG Downgrades Avita Medical Ltd. (RCEL) to Neutral
April 11, 2024 5:38 AM EDTBTIG analyst Ryan Zimmerman downgraded Avita Medical Ltd. (NASDAQ: RCEL) from Buy to Neutral.
The analyst comments "We downgrade RCEL shares to Neutral from Buy and remove our PT. RCEL announced 1Q24 rev. is expected to be $11.0M-$11.3M, ~26.1% - 28.1% below Cons. estimates and the guidance provided on the 4Q23 call of $14.8M - $15.6M. BTIG/Street expectations going into 1Q24 were $15.2M/$15.3M. Mgmt. noted the reduction in 1Q24 guidance was due to the slower-than-expected conversion rate of new accounts for full-thickness skin defects. We model flat product... More
